Press Releases
CATALYST BIOSCIENCES AND WYETH PHARAMCEUTICALS ANNOUNCE WORLDWIDE COLLABORATION
Collegeville, PA and South San Francisco, CA, June 30, 2009 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc. today announced that the two companies have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.
CATALYST BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD WITH LEADING EXPERTS IN PROTEASE THERAPEUTIC DISCOVERY AND DEVELOPMENT
South San Francisco, CA, March 24, 2009 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has appointed four new members to the company’s Scientific Advisory Board (SAB). Robert J. Fletterick, Ph.D., David Ginsburg M.D., Guy S. Salvesen, Ph.D., and Gregory Stahl, Ph.D., join initial members Shaun Coughlin, M.D., Ph.D., Charles Craik, Ph.D., and James Wells, Ph.D.
CATALYST BIOSCIENCES RAISES $40 MILLION IN SERIES C FINANCING
South San Francisco, CA, December 3, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has raised $40.4 million in a Series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures. More»
CATALYST BIOSCIENCES APPOINTS DR. TODD LORENZ CHIEF MEDICAL OFFICER
South San Francisco, CA, October 28, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has appointed Todd Lorenz, M.D., as the company’s Chief Medical Officer. Dr. Lorenz’s career encompasses nearly 20 years of experience focused on the clinical development of novel medicines. More»
CATALYST
BIOSCIENCES SELECTS DRUG DEVELOPMENT CANDIDATE IN FACTOR VIIA
PROGRAM FOR HEMOPHILIA
South
San Francisco, CA, May 6, 2008 - Catalyst
Biosciences, Inc., a pioneer in the discovery and development of
engineered proteases known as Alterase™ therapeutics, announced
that it has selected CB 813, an improved, second-generation variant
of human coagulation factor VIIa, as a development candidate
for the treatment of acute bleeding in hemophilia patients. More»
South San Francisco, CA, January 7, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, today announced that it has entered into an exclusive worldwide research and license agreement with Centocor Research & Development, Inc. More»
CATALYST BIOSCIENCES APPOINTS ERIK WIBERG TO CHIEF FINANCIAL OFFICER
South
San Francisco, CA, February 1, 2007 – Catalyst Biosciences, Inc., a biotechnology company focused on engineering and developing novel therapeutic protease products, today appointed Erik Wiberg as the company’s Chief Financial Officer. Mr. Wiberg brings a significant financial and business background in the life sciences sector especially in the areas of business development, M & A
and finance. More»
South San Francisco, CA, January 7, 2007 – Catalyst Biosciences, Inc., today announced that it has signed two research collaboration and license agreements with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), having potential total payments of up to $100 million, exclusive of potential royalty payments. More »
CATALYST ANNOUNCES APPOINTMENT OF MARC NAVRE, PH.D. TO VICE PRESIDENT DRUG DISCOVERY
South San Francisco, CA, May 23, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and devloping novel therapeutic protease products, today announced that Marc Navre, Ph.D. has been appointed as the company's Vice President of Drug Discovery. More »
CATALYST ANNOUNCES APPOINTMENT OF NASSIM USMAN AS CEO
South San Francisco, CA, February 22, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease products, today announced that Nassim Usman, Ph.D., has been named the Company's Chief Executive Officer. More »
CATALYST ANNOUNCES APPOINTMENT AND PROMOTION OF SENIOR EXECUTIVES
South San Francisco, CA, February 10, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease products, today announced the promotion of Edwin Madison, Ph.D. to Chief Scientific Officer and the appointment of Roger Thomas, Ph.D. as Vice President, Preclinical Research. More »
CATALYST BIOSCIENCES RAISES $30 MILLION SERIES B FINANCING TO ADVANCE THERAPEUTIC PROTEASES
South San Francisco, CA, February 9, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease producs, today announced it has raised $30 million in its Series B financing. More »
CATALYST BIOSCIENCES LICENSES SEMINAL INTELLECTUAL PROPERTY IN THE FIELD OF PROTEASE THERAPEUTICS
South San Francisco, CA and San Diego, CA, July 25, 2005 – Catalyst Biosciences, Inc. and Torrey Pines Institute for Molecular Studies announced today that they have entered into an exclusive worldwide license agreement for Catalyst’s use of the Institute’s seminal intellectual property covering protease engineering, selection and optimization. More »
CATALYST
BIOSCIENCES RAISES $10 MILLION IN SERIES A FINANCING
October 28, 2004 - Catalyst Biosciences, Inc., a protein therapeutics company,
today announced that it has closed a Series A round of funding at $10.3 million.
Sofinnova Ventures led the financing, which also included Burrill and Company,
RCT Bioventures and Novartis Venture Fund. Catalyst will use the financing
to move its research and development programs through pre-clinical animal models
toward clinical development, to expand its technology and infrastructure platform,
and to add key personnel and laboratory space. More »
TECHNOLOGY REVIEW MAGAZINE NAMES
SANDRA WAUGH RUGGLES ONE OF THE WORLD'S TOP YOUNG INNOVATORS
September 20, 2004 - Catalyst Biosciences, a protein therapeutics company, today announced that
its co-founder, Sandra Waugh Ruggles, Ph.D., has been named to the 2004 list
of the
world's 100 Top Young Innovators by Technology Review, MIT's Magazine of
Innovation. The TR100, chosen by the editors of Technology Review and a panel
of judges,
consists of 100 individuals under age 35 whose innovative work in technology
has a notable impact on today's world. This year's nominees are recognized
for their contributions in transforming the nature of technology and business
in
industries such as biotechnology and medicine, computing, and nanotechnology.
More »
